<DOC>
	<DOCNO>NCT02173899</DOCNO>
	<brief_summary>The purpose study observe occurrence adverse event , seroconversion rate geometric mean titre ( GMTs ) 2 dos live attenuate varicella vaccine .</brief_summary>
	<brief_title>Immunogenicity Safety 2 Doses Live Attenuated Varicella Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Parent/legal acceptable representative willing able understand protocol requirement provide informed consent Participant age ≥ 1 year ≤ 7 year Participant without preventive inoculation varicella vaccine previous history chickenpox zoster Subject parent/guardian able attend schedule visit comply trial procedure Body temperature ≤ 37.5℃ Known allergy constituent vaccine Known acute illness , severe chronic disease , acute exacerbation chronic disease fever Known suspect impairment immunologic function , receipt immunosuppressive therapy immunoglobulin since birth Reported history allergy , convulsion , epilepsy , mental illness brain disease clear serious systemic reaction Failed Expanded Programme Immunization ( EPI ) Receipt vaccine 4 week precede trial vaccination Plan receive vaccine 4 week follow trial vaccination Known bleeding disorder Receipt whole blood , blood plasma immunoglobulin 5 month precede trial vaccination Reported history acute illness need systemic antibiotic antiviral treatment infection 7 day precede trial vaccination An acute illness without fever ( temperature ≥ 38.0℃ ) 3 day precede enrollment trial Participation interventional clinical trial Any condition , opinion investigator , would pose health risk subject interfere vaccine</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>